Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?
Saved in:
| Title: | Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer? |
|---|---|
| Authors: | Morgans AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address: Aliciak_morgans@dfci.harvard.edu., Touya M; Astellas Pharma Inc., Northbrook, IL., El-Chaar N; Astellas Pharma Inc., Northbrook, IL., ElSouda D; Astellas Pharma Inc., Northbrook, IL., Mucha L; Astellas Pharma Inc., Northbrook, IL., Ramaswamy K; Pfizer Inc., New York, NY., Adejumo KL; Cardinal Health, Dublin, OH., Schuler T; Cardinal Health, Dublin, OH., Sharpe J; Cardinal Health, Dublin, OH., Feinberg B; Cardinal Health, Dublin, OH., Asgarisabet P; Cardinal Health, Dublin, OH., Pathak P; Cardinal Health, Dublin, OH., Freedland SJ; Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Durham VA Health Care System, Durham, NC. |
| Source: | Clinical genitourinary cancer [Clin Genitourin Cancer] 2026 Mar; Vol. 24 (2), pp. 102496. Date of Electronic Publication: 2026 Jan 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
